Evidence map›Paper›PMID 35978820›Full record

ArticleFrontiers in oncology2022

LCS-1 inhibition of superoxide dismutase 1 induces ROS-dependent death of glioma cells and degradates PARP and BRCA1.

Min Ling, Qing Liu, Yufei Wang, Xueting Liu, Manli Jiang, Jinyue Hu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. eLife · 2024
    Article
  7. bioRxiv : the preprint server for biology · 2024
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Min LingDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Qing LiuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Yufei WangDepartment of Clinical Laboratory, Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Xueting LiuMedical Research Center, Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Manli JiangMedical Research Center, Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Jinyue HuMedical Research Center, Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Changsha Central Hospital · CNUniversity of South China · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas are characterized by high morbidity and mortality, and have only slightly increased survival with recent considerable improvements for treatment. An innovative therapeutic strategy had been developed

Indexed as

BRCA1cell deathgliomaLCS-1PARPROSSOD1

Identifiers

PMID35978820
PMCPMC9376264
OpenAlexW4289130589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.